Pre-clinical experimentation and clinical research
Pre-clinical experimentation and clinical research
Contact
Arronax Nantes > Pre-clinical experimentation and clinical research > Our publications > Article

Preclinical experimentation and clinical research

  • FDG-PET/CT in Lymphoma: Where Do We Go Now?, Al Tabaa, Y ; Bailly, C ; Kanoun, S, Cancers (Basel), 2021, 13
    https://doi.org/10.3390/cancers13205222

  • Immuno-PET: Design options and clinical proof-of-concept, Lugat, A ; Bailly, C ; Chérel, M ; Rousseau, C ; Kraeber-Bodéré, F ; Bodet-Milin, C & al, Front Med (Lausanne), 2022, 9, 1026083
    https://doi.org/10.3389/fmed.2022.1026083

  • Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma, Bailly, C ; Carlier, T ; Tessoulin, B ; Gastinne, T ; Kraeber-Bodere, F ; Le Gouill, S & al , Hematol Oncol, 2022, 40, 796-800
    https://doi.org/10.1002/hon.2965

  • Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study, Alberge JB, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Béné MC, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. (DA), J Nucl Med, 2022, 63, 1008-1013
    https://doi.org/10.2967/jnumed.121.262884

  • Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study, Kraeber-Bodéré, F ; Zweegman, S ; Perrot, A ; Hulin, C ; Caillot, D ; Facon, T & al , Haematologica, 2022
    https://doi.org/10.3324/haematol.2021.280051

  • Promising Clinical Performance of Pretargeted Immuno-PET with Anti-CEA Bispecific Antibody and Gallium-68-Labelled IMP-288 Peptide for Imaging Colorectal Cancer Metastases: A Pilot Study, Touchefeu, Y.; Bailly, C.; Frampas, E.; Eugène, T.; Rousseau, C.; Bourgeois, M.; Bossard, C.; Faivre-Chauvet, A.; Rauscher, A.; Masson, D.; David, A.; Cerato, E.; Carlier, T.; Sharkey, R. M.; Goldenberg, D. M.; Barbet, J.; Kraeber-Bodere, F.; Bodet-Milin, C., Eur J Nucl Med Mol Imaging 2021, 48 (3), 874–882. doi:10.1007/s00259-020-04989-3

  • Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the IPET-MTC Study, Bodet-Milin, C.; Faivre-Chauvet, A.; Carlier, T.; Ansquer, C.; Rauscher, A.; Frampas, E.; Toulgoat, F.; Masson, D.; Bourgeois, M.; Cerato, E.; Rohmer, V.; Couturier, O.; Drui, D.; Goldenberg, D. M.; Sharkey, R. M.; Barbet, J.; Kraeber-Bodere, F., J Nucl Med 2021, 62 (9), 1221–1227. doi:10.2967/jnumed.120.252791

  •  Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety, Delage JA, Gnesin S, Prior JO, Barbet J, Le Saëc P, Marionneau-Lambot S, Gouard S, Chérel M, Bourgeois M, Schaefer N, Viertl D, Fierle JK, Dunn SM, Faivre-Chauvet A. Cancers (Basel). 2021 Nov 25;13(23):5936.
    doi:10.3390/cancers13235936

  • Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model, Delage JA, Faivre-Chauvet A, Barbet J, Fierle JK, Schaefer N, Coukos G, Viertl D, Dunn SM, Gnesin S, Prior JO, Pharmaceutics, 2021 Jan 13;13(1):96. doi: 10.3390/pharmaceutics13010096

  • Cell Tracking in Cancer Immunotherapy, Perrin J, Capitao M, Mougin-Degraef M, Guérard F, Faivre-Chauvet A, Rbah-Vidal L, et al, Front Med. 14 févr 2020;7:34. https://doi.org/10.3389/fmed.2020.00034

see more results